Odyssey Therapeutics, Inc.
ODTX
$19.21
$0.321.67%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -7.57% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | -15.10% | ||||
| Operating Income | 11.46% | ||||
| Income Before Tax | 0.25% | ||||
| Income Tax Expenses | -55.00% | ||||
| Earnings from Continuing Operations | 0.45% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 0.45% | ||||
| EBIT | 11.46% | ||||
| EBITDA | 11.51% | ||||
| EPS Basic | 82.82% | ||||
| Normalized Basic EPS | 85.04% | ||||
| EPS Diluted | 82.82% | ||||
| Normalized Diluted EPS | 85.04% | ||||
| Average Basic Shares Outstanding | 479.42% | ||||
| Average Diluted Shares Outstanding | 479.42% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||